PURPOSE: The National Cancer Institute-funded cooperative oncology group trials have improved overall survival for children with cancer from 10% to 85% and have set standards of care for adults with malignancies. Despite these successes, cooperative oncology groups currently face substantial challenges. We are working to develop methods to improve the efficiency and effectiveness of these trials. Specifically, we merged data from the Children's Oncology Group (COG) and the Pediatric Health Information Systems (PHIS) to improve toxicity monitoring, to estimate treatment-associated resource utilization and costs, and to address important clinical epidemiology questions. METHODS: COG and PHIS data on patients enrolled on a phase III COG trial for de novo acute myeloid leukemia at 43 PHIS hospitals were merged using a probabilistic algorithm. Resource utilization summary statistics were then tabulated for the first chemotherapy course based on PHIS data. RESULTS: Of 416 patients enrolled on the phase III COG trial at PHIS centers, 392 (94%) were successfully matched. Of these, 378 (96%) had inpatient PHIS data available beginning at the date of study enrollment. For these, daily blood product usage and anti-infective exposures were tabulated and standardized costs were described. CONCLUSIONS: These data demonstrate that patients enrolled in a cooperative group oncology trial can be successfully identified in an administrative data set and that supportive care resource utilization can be described. Further work is required to optimize the merging algorithm, map resource utilization metrics to the National Cancer Institute Common Toxicity Criteria for monitoring toxicity, to perform comparative effectiveness studies, and to estimate the costs associated with protocol therapy.
PURPOSE: The National Cancer Institute-funded cooperative oncology group trials have improved overall survival for children with cancer from 10% to 85% and have set standards of care for adults with malignancies. Despite these successes, cooperative oncology groups currently face substantial challenges. We are working to develop methods to improve the efficiency and effectiveness of these trials. Specifically, we merged data from the Children's Oncology Group (COG) and the Pediatric Health Information Systems (PHIS) to improve toxicity monitoring, to estimate treatment-associated resource utilization and costs, and to address important clinical epidemiology questions. METHODS:COG and PHIS data on patients enrolled on a phase III COG trial for de novo acute myeloid leukemia at 43 PHIS hospitals were merged using a probabilistic algorithm. Resource utilization summary statistics were then tabulated for the first chemotherapy course based on PHIS data. RESULTS: Of 416 patients enrolled on the phase III COG trial at PHIS centers, 392 (94%) were successfully matched. Of these, 378 (96%) had inpatient PHIS data available beginning at the date of study enrollment. For these, daily blood product usage and anti-infective exposures were tabulated and standardized costs were described. CONCLUSIONS: These data demonstrate that patients enrolled in a cooperative group oncology trial can be successfully identified in an administrative data set and that supportive care resource utilization can be described. Further work is required to optimize the merging algorithm, map resource utilization metrics to the National Cancer Institute Common Toxicity Criteria for monitoring toxicity, to perform comparative effectiveness studies, and to estimate the costs associated with protocol therapy.
Authors: Brian T Fisher; Theoklis E Zaoutis; Kateri H Leckerman; Russell Localio; Richard Aplenc Journal: Pediatr Blood Cancer Date: 2010-10 Impact factor: 3.167
Authors: Eric I Benchimol; Douglas G Manuel; Teresa To; Anne M Griffiths; Linda Rabeneck; Astrid Guttmann Journal: J Clin Epidemiol Date: 2010-12-30 Impact factor: 6.437
Authors: Lee D Kaiser; Allen S Melemed; Alaknanda J Preston; Hilary A Chaudri Ross; Donna Niedzwiecki; Gwendolyn A Fyfe; Jacqueline M Gough; William D Bushnell; Cynthia L Stephens; M Kelsey Mace; Jeffrey S Abrams; Richard L Schilsky Journal: J Clin Oncol Date: 2010-10-04 Impact factor: 44.544
Authors: Michelle R Mahoney; Daniel J Sargent; Michael J O'Connell; Richard M Goldberg; Paul Schaefer; Jan C Buckner Journal: J Clin Oncol Date: 2005-12-20 Impact factor: 44.544
Authors: Todd M Cooper; Janet Franklin; Robert B Gerbing; Todd A Alonzo; Craig Hurwitz; Susana C Raimondi; Betsy Hirsch; Franklin O Smith; Prasad Mathew; Robert J Arceci; James Feusner; Robert Iannone; Robert S Lavey; Soheil Meshinchi; Alan Gamis Journal: Cancer Date: 2011-07-15 Impact factor: 6.860
Authors: Elizabeth B Lamont; James E Herndon; Jane C Weeks; I Craig Henderson; Rogerio Lilenbaum; Richard L Schilsky; Nicholas A Christakis Journal: J Natl Cancer Inst Date: 2005-07-20 Impact factor: 13.506
Authors: Brian T Fisher; Richard Aplenc; Russell Localio; Kateri H Leckerman; Theoklis E Zaoutis Journal: Pediatr Infect Dis J Date: 2009-11 Impact factor: 2.129
Authors: Tamara P Miller; Brian T Fisher; Kelly D Getz; Leah Sack; Hanieh Razzaghi; Alix E Seif; Rochelle Bagatell; Peter C Adamson; Richard Aplenc Journal: Pediatr Blood Cancer Date: 2019-04-09 Impact factor: 3.167
Authors: Marko Kavcic; Brian T Fisher; Yimei Li; Alix E Seif; Kari Torp; Dana M Walker; Yuan-Shung Huang; Grace E Lee; Sarah K Tasian; Marijana Vujkovic; Rochelle Bagatell; Richard Aplenc Journal: Cancer Date: 2013-02-21 Impact factor: 6.860
Authors: Tamara P Miller; Yimei Li; Marko Kavcic; Kelly D Getz; Yuan-Shun V Huang; Lillian Sung; Todd A Alonzo; Robert Gerbing; Marla H Daves; Terzah M Horton; Michael A Pulsipher; Jessica Pollard; Rochelle Bagatell; Alix E Seif; Brian T Fisher; Selina Luger; Alan S Gamis; Peter C Adamson; Richard Aplenc Journal: Haematologica Date: 2017-06-22 Impact factor: 9.941
Authors: Yimei Li; Joanna G Newton; Kelly D Getz; Yuan-Shung Huang; Alix E Seif; Brian T Fisher; Richard Aplenc; Lena E Winestone Journal: Pediatr Blood Cancer Date: 2018-12-26 Impact factor: 3.167
Authors: Lena E Winestone; Kelly D Getz; Pooja Rao; Yimei Li; Matt Hall; Yuan-Shung V Huang; Alix E Seif; Brian T Fisher; Richard Aplenc Journal: Leuk Lymphoma Date: 2019-02-07
Authors: Tamara P Miller; Andrea B Troxel; Yimei Li; Yuan-Shung Huang; Todd A Alonzo; Robert B Gerbing; Matt Hall; Kari Torp; Brian T Fisher; Rochelle Bagatell; Alix E Seif; Lillian Sung; Alan Gamis; David Rubin; Selina Luger; Richard Aplenc Journal: Pediatr Blood Cancer Date: 2015-03-11 Impact factor: 3.167
Authors: Staci D Arnold; Ruta Brazauskas; Naya He; Yimei Li; Matt Hall; Yoshiko Atsuta; Jignesh Dalal; Theresa Hahn; Nandita Khera; Carmem Bonfim; Shahrukh Hashmi; Susan Parsons; William A Wood; Amir Steinberg; César O Freytes; Christopher E Dandoy; David I Marks; Hillard M Lazarus; Hisham Abdel-Azim; Menachem Bitan; Miguel Angel Diaz; Richard F Olsson; Usama Gergis; Adriana Seber; Baldeep Wirk; C Fred LeMaistre; Celalettin Ustun; Christine Duncan; David Rizzieri; David Szwajcer; Franca Fagioli; Haydar Frangoul; Jennifer M Knight; Rammurti T Kamble; Paulette Mehta; Raquel Schears; Prakash Satwani; Michael A Pulsipher; Richard Aplenc; Wael Saber Journal: Biol Blood Marrow Transplant Date: 2020-05-25 Impact factor: 5.742
Authors: Shannon L Maude; Julie C Fitzgerald; Brian T Fisher; Yimei Li; Yuan-Shung Huang; Kari Torp; Alix E Seif; Marko Kavcic; Dana M Walker; Kateri H Leckerman; Todd J Kilbaugh; Susan R Rheingold; Lillian Sung; Theoklis E Zaoutis; Robert A Berg; Vinay M Nadkarni; Neal J Thomas; Richard Aplenc Journal: Pediatr Crit Care Med Date: 2014-02 Impact factor: 3.624
Authors: Brian T Fisher; Sonia Singh; Yuan-Shung Huang; Yimei Li; John Gregory; Dana Walker; Alix E Seif; Marko Kavcic; Richard Aplenc Journal: Pediatr Blood Cancer Date: 2013-07-18 Impact factor: 3.167
Authors: Pooja Rao; Yimei Li; Kelly D Getz; Tamara P Miller; Yuan-Shung Huang; Jennifer J Wilkes; Alix E Seif; Rochelle Bagatell; Brian T Fisher; Clarisa Gracia; Richard Aplenc Journal: Cancer Date: 2016-09-12 Impact factor: 6.860